Loading...
Prospective Multicenter Phase II Trial of Systemic ADH-1 in Combination With Melphalan via Isolated Limb Infusion in Patients With Advanced Extremity Melanoma
PURPOSE: Isolated limb infusion (ILI) with melphalan (M-ILI) dosing corrected for ideal body weight (IBW) is a well-tolerated treatment for patients with in-transit melanoma with a 29% complete response rate. ADH-1 is a cyclic pentapeptide that disrupts N-cadherin adhesion complexes. In a preclinica...
Na minha lista:
| Udgivet i: | J Clin Oncol |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Clinical Oncology
2011
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4668281/ https://ncbi.nlm.nih.gov/pubmed/21343562 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.32.1224 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|